BeiGeneius Hematology Summit – CLL
An expert multidisciplinary panel review the latest developments in CLL and the evolving role of BTK inhibitors via an interactive agenda including presentations, ‘Ask the Experts’ sessions and workshops.
Patient evaluation and risk stratification
First-line treatment for CLL: An evolving landscape
Treating relapsed/refractory CLL
CLL and the immune system: Infections, vaccines, and autoimmune disease
Cardiovascular toxicities associated with BTK inhibitors
Updates in CLL from ASH 2022



